Innate, Sanofi licensing deal gets US antitrust clearance

Jan. 25, 2023 4:26 AM ETInnate Pharma S.A. (IPHA), SNYBy: Ravikash, SA News Editor

FRANCE-ECONOMY-PHARMACEUTICAL-SANOFI-LOGO

ERIC PIERMONT/AFP via Getty Images

  • Innate Pharma (NASDAQ:IPHA) and Sanofi (NASDAQ:SNY) said the expansion of their collaboration on natural killer (NK) cell engagers under a licensing agreement became effective as the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.